Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer

results of a prospective study

G. Arpino, A. Michelotti, Mauro Truini, Filippo Montemurro, Stefania Russo, Raffaella Palumbo, Claudio Zamagni, Agnese Carmela Latorre, Dario Bruzzese, Fernando Riccardi, Michelino De Laurentiis, Alessandra Beano, Laura Biganzoli, Alberto Zaniboni, Lucio Laudadio, Maria Malagoli, D. Bilancia, Francesco Schettini, M. Giuliano, Marina Cazzaniga & 1 others S. De Placido

Research output: Contribution to journalArticle

Abstract

Background: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC. Patients and methods: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CP patients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CP patients were compared by using the Cochran Q statistics. Results: Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 %; p 2 cm (T ≥ 2 cm 39 vs. 59 %; p

Original languageEnglish
Pages (from-to)669-678
Number of pages10
JournalJournal of Cancer Research and Clinical Oncology
Volume142
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Demography
Clinical Trials
Prospective Studies
Breast Neoplasms
Randomized Controlled Trials
Neoplasms
Patient Advocacy
Progesterone Receptors
Estrogen Receptors
Delivery of Health Care
Therapeutics

Keywords

  • Adjuvant therapy
  • Clinical practice
  • Early breast cancer
  • HER2
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer : results of a prospective study. / Arpino, G.; Michelotti, A.; Truini, Mauro; Montemurro, Filippo; Russo, Stefania; Palumbo, Raffaella; Zamagni, Claudio; Latorre, Agnese Carmela; Bruzzese, Dario; Riccardi, Fernando; De Laurentiis, Michelino; Beano, Alessandra; Biganzoli, Laura; Zaniboni, Alberto; Laudadio, Lucio; Malagoli, Maria; Bilancia, D.; Schettini, Francesco; Giuliano, M.; Cazzaniga, Marina; De Placido, S.

In: Journal of Cancer Research and Clinical Oncology, Vol. 142, No. 3, 01.03.2016, p. 669-678.

Research output: Contribution to journalArticle

Arpino, G, Michelotti, A, Truini, M, Montemurro, F, Russo, S, Palumbo, R, Zamagni, C, Latorre, AC, Bruzzese, D, Riccardi, F, De Laurentiis, M, Beano, A, Biganzoli, L, Zaniboni, A, Laudadio, L, Malagoli, M, Bilancia, D, Schettini, F, Giuliano, M, Cazzaniga, M & De Placido, S 2016, 'Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study', Journal of Cancer Research and Clinical Oncology, vol. 142, no. 3, pp. 669-678. https://doi.org/10.1007/s00432-015-2033-z
Arpino, G. ; Michelotti, A. ; Truini, Mauro ; Montemurro, Filippo ; Russo, Stefania ; Palumbo, Raffaella ; Zamagni, Claudio ; Latorre, Agnese Carmela ; Bruzzese, Dario ; Riccardi, Fernando ; De Laurentiis, Michelino ; Beano, Alessandra ; Biganzoli, Laura ; Zaniboni, Alberto ; Laudadio, Lucio ; Malagoli, Maria ; Bilancia, D. ; Schettini, Francesco ; Giuliano, M. ; Cazzaniga, Marina ; De Placido, S. / Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer : results of a prospective study. In: Journal of Cancer Research and Clinical Oncology. 2016 ; Vol. 142, No. 3. pp. 669-678.
@article{1d2bc8a0f6564265b9fa815e3f285b7a,
title = "Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study",
abstract = "Background: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC. Patients and methods: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CP patients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CP patients were compared by using the Cochran Q statistics. Results: Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 {\%}; p 2 cm (T ≥ 2 cm 39 vs. 59 {\%}; p",
keywords = "Adjuvant therapy, Clinical practice, Early breast cancer, HER2, Trastuzumab",
author = "G. Arpino and A. Michelotti and Mauro Truini and Filippo Montemurro and Stefania Russo and Raffaella Palumbo and Claudio Zamagni and Latorre, {Agnese Carmela} and Dario Bruzzese and Fernando Riccardi and {De Laurentiis}, Michelino and Alessandra Beano and Laura Biganzoli and Alberto Zaniboni and Lucio Laudadio and Maria Malagoli and D. Bilancia and Francesco Schettini and M. Giuliano and Marina Cazzaniga and {De Placido}, S.",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00432-015-2033-z",
language = "English",
volume = "142",
pages = "669--678",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer

T2 - results of a prospective study

AU - Arpino, G.

AU - Michelotti, A.

AU - Truini, Mauro

AU - Montemurro, Filippo

AU - Russo, Stefania

AU - Palumbo, Raffaella

AU - Zamagni, Claudio

AU - Latorre, Agnese Carmela

AU - Bruzzese, Dario

AU - Riccardi, Fernando

AU - De Laurentiis, Michelino

AU - Beano, Alessandra

AU - Biganzoli, Laura

AU - Zaniboni, Alberto

AU - Laudadio, Lucio

AU - Malagoli, Maria

AU - Bilancia, D.

AU - Schettini, Francesco

AU - Giuliano, M.

AU - Cazzaniga, Marina

AU - De Placido, S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC. Patients and methods: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CP patients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CP patients were compared by using the Cochran Q statistics. Results: Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 %; p 2 cm (T ≥ 2 cm 39 vs. 59 %; p

AB - Background: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC. Patients and methods: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CP patients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CP patients were compared by using the Cochran Q statistics. Results: Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 %; p 2 cm (T ≥ 2 cm 39 vs. 59 %; p

KW - Adjuvant therapy

KW - Clinical practice

KW - Early breast cancer

KW - HER2

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84957944737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957944737&partnerID=8YFLogxK

U2 - 10.1007/s00432-015-2033-z

DO - 10.1007/s00432-015-2033-z

M3 - Article

VL - 142

SP - 669

EP - 678

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 3

ER -